Treatment of synucleinopathies
AssigneesDeutsches Zentrum für Neurodegenerative Erkrankungen e. V. (DZNE), Klinikum Rechts Der Isar Der Technischen UniversitäT MüNchen
InventorsGünter Höglinger, Matthias Höllerhage, Thomas Werner Rösler
Life of this patent
Estimating the term…
Abstract
A modulator of PDE1A and/or PDE1C can be used as a medicament, in particular in the prevention or treatment of synucleinopathies, such as multiple system atrophy, dementia with Lewy bodies, Parkinson's disease, pure autonomic failure, rapid eye movement sleep behavior disorder, inherited synucleinopathies caused by mutations or multiplications of the SNCA gene, or synucleinopathies caused by mutations in other genes including, but not limited to, GBA, LRRK2 and PARK2.
Claims12
A method for treating a synucleinopathy in a human or non-human animal in need thereof, comprising:
- administering a compound to said human or said non-human animal,
- wherein the compound is a PDE1A modulator and/or a PDE1C modulator,
- wherein the compound is represented by the following formula (I):
- wherein
- R1 is halo,
- a is 0, 1, 2, or 3,
- R2 is selected from the group consisting of —H and —(C1-C6)alkyl,
- R3 and R4 are independently selected from the group consisting of —H, —OH, —(C1-C6)alkyl, and —(C1-C6)-hydroxyalkyl, or
- R3 and R4 taken together are ═O, or
- R2 and R3 together with the nitrogen atom and carbon atom they are attached to form a 6-membered heterocyclic ring which is optionally substituted,
- R5 and R6 are independently selected from the group consisting of —H and —(C1-C6)alkyl, or
- R5 and R6 taken together form a carbon-carbon bond,
- or a pharmaceutically acceptable salt thereof,
- wherein the alkyl and hydroxyalkyl groups are optionally substituted,
- wherein the synucleinopathy is multiple system atrophy (MSA), dementia with Lewy bodies (DLB), pure autonomic failure (PAF), rapid eye movement sleep behavior disorder (RBD), or synucleinopathies caused by mutations in genes other than SNCA.
The method of c the synucleinopathy is MSA, wherein the MSA is MSA with predominantly cerebellar symptoms (MSA-C) or MSA with predominantly parkinsonian symptoms (MSA-P).
A method for treatment of a synucleinopathy in a human or a non-human in need thereof, comprising:
- administering vinpocetine to said human or non-human animal,
- wherein the synucleinopathy is selected from the group consisting of multiple system atrophy (MSA), dementia with Lewy bodies (DLB), pure autonomic failure (PAF), rapid eye movement sleep behavior disorder (RBD), and synucleinopathies caused by mutations in genes other than SNCA.
Dependencies are inferred from the claim text.